| scholarly article | Q13442814 |
| P50 | author | Avi Rosenberg | Q37366935 |
| Jeffrey B. Kopp | Q38359650 | ||
| P2860 | cites work | Corticosteroid therapy for nephrotic syndrome in children | Q24187231 |
| Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children | Q24202861 | ||
| Immunosuppressive treatment for focal segmental glomerulosclerosis in adults | Q24242266 | ||
| Disruption of PTPRO causes childhood-onset nephrotic syndrome | Q24309282 | ||
| Association of trypanolytic ApoL1 variants with kidney disease in African Americans | Q24606581 | ||
| APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy | Q24631837 | ||
| Practical Application of Columbia Classification for Focal Segmental Glomerulosclerosis | Q26744237 | ||
| Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades | Q26752836 | ||
| Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis | Q26753833 | ||
| A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues | Q26776389 | ||
| Chronic kidney disease in congenital heart disease patients: a narrative review of evidence | Q26798956 | ||
| Treatment of primary FSGS in adults | Q26828859 | ||
| Expression of synaptopodin and GLEPP1 as markers of steroid responsiveness in primary focal segmental glomerulosclerosis | Q28303824 | ||
| ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing | Q29616235 | ||
| Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy | Q30702085 | ||
| Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States | Q31121770 | ||
| A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. | Q33179291 | ||
| Gene Expression Profiles of Podocyte-Associated Molecules as Diagnostic Markers in Acquired Proteinuric Diseases | Q33194073 | ||
| Development of focal segmental glomerulosclerosis after anabolic steroid abuse | Q33562274 | ||
| Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group | Q33584368 | ||
| Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis | Q33872298 | ||
| A spectrum of morphologic lesions of focal segmental glomerulosclerosis by Columbia criteria in human immunodeficiency virus infection | Q45359194 | ||
| Collapsing glomerulopathy following anthracycline therapy. | Q45918343 | ||
| Combined angiotensin inhibition for the treatment of diabetic nephropathy | Q46129784 | ||
| HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes | Q46219099 | ||
| Low birthweight and premature birth are risk factors for podocytopenia and focal segmental glomerulosclerosis | Q46331877 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study | Q46910108 | ||
| The Importance of Sample Size in the Interpretation of the Renal Biopsy | Q47185105 | ||
| Krüppel-Like Factor 15 Mediates Glucocorticoid-Induced Restoration of Podocyte Differentiation Markers | Q48052536 | ||
| Renin-angiotensin-aldosterone system inhibitors in pediatric focal segmental glomerulosclerosis | Q48799925 | ||
| Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. | Q50467799 | ||
| Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. | Q50605578 | ||
| Presenting features and short-term outcome according to pathologic variant in childhood primary focal segmental glomerulosclerosis. | Q51741626 | ||
| Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). | Q51808864 | ||
| Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. | Q53451940 | ||
| Secondary collapsing glomerulopathy associated with Loa loa filariasis. | Q54128918 | ||
| Glomerular dynamics and morphology of aged spontaneously hypertensive rats. Effects of angiotensin-converting enzyme inhibition. | Q54180764 | ||
| Pathologic classification of focal segmental glomerulosclerosis: a working proposal | Q56008651 | ||
| Angiotensin II Type 1 Receptor Blockade Inhibits the Development and Progression of HIV-Associated Nephropathy in a Mouse Model | Q57691250 | ||
| Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis | Q57691283 | ||
| Sirolimus Therapy of Focal Segmental Glomerulosclerosis Is Associated With Nephrotoxicity | Q57691291 | ||
| Is focal segmental glomerulosclerosis really focal? Distribution of lesions in adults and children | Q71979453 | ||
| Clinical course of focal segmental glomerulosclerosis associated with hepatosplenic schistosomiasis mansoni | Q72173708 | ||
| A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis | Q74487217 | ||
| Progression of glomerular diseases: is the podocyte the culprit? | Q77291496 | ||
| Renin-angiotensin axis blockade reduces proteinuria in presymptomatic patients with familial FSGS | Q80387822 | ||
| High sirolimus levels may induce focal segmental glomerulosclerosis de novo | Q80797353 | ||
| [Synaptopodin immunoexpression in steroid-responsive and steroid-resistant minimal change disease and focal segmental glomerulosclerosis] | Q80859537 | ||
| Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study | Q83699263 | ||
| Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells | Q83948540 | ||
| Resolution of recurrent focal segmental glomerulosclerosis after retransplantation | Q83991578 | ||
| Serum-soluble urokinase receptor concentration in primary FSGS | Q84033601 | ||
| New players in the pathogenesis of focal segmental glomerulosclerosis | Q84531641 | ||
| Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis | Q86084087 | ||
| Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis | Q86215247 | ||
| Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis | Q86998557 | ||
| Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome | Q87105700 | ||
| Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children | Q87407965 | ||
| An update on the treatment options for focal segmental glomerulosclerosis | Q94857026 | ||
| The incidence of biopsy-proven glomerulonephritis in Australia. | Q34294024 | ||
| Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis | Q34418531 | ||
| A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome | Q34445136 | ||
| A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation | Q34498293 | ||
| Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants | Q34499836 | ||
| Dystroglycan in the diagnosis of FSGS. | Q34659224 | ||
| Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1 | Q35033687 | ||
| A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease | Q35132279 | ||
| Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort | Q35278415 | ||
| Glomerular hyperfiltration and albuminuria in children with sickle cell anemia | Q35278672 | ||
| A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation | Q35379384 | ||
| Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial | Q35658566 | ||
| A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis | Q35669295 | ||
| Focal segmental glomerulosclerosis: molecular genetics and targeted therapies | Q35686453 | ||
| Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group | Q35704498 | ||
| Trends in the histopathology of childhood nephrotic syndrome in Ibadan Nigeria: preponderance of idiopathic focal segmental glomerulosclerosis | Q35869275 | ||
| Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series | Q35976834 | ||
| Role of Myeloid-Derived Suppressor Cells in Glucocorticoid-Mediated Amelioration of FSGS. | Q36003095 | ||
| Growth-dependent podocyte failure causes glomerulosclerosis | Q36109205 | ||
| APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans | Q36223249 | ||
| Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid-Resistant Nephrotic Syndrome | Q36543103 | ||
| IgM contributes to glomerular injury in FSGS | Q36638347 | ||
| Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS | Q36686985 | ||
| Changing the Paradigm for the Treatment and Development of New Therapies for FSGS. | Q36717656 | ||
| The spectrum of podocytopathies: a unifying view of glomerular diseases. | Q36780741 | ||
| A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases | Q36910589 | ||
| The podocyte as a direct target for treatment of glomerular disease? | Q37139449 | ||
| Focal segmental glomerulosclerosis is associated with a PDSS2 haplotype and, independently, with a decreased content of coenzyme Q10. | Q37234710 | ||
| Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. | Q37359035 | ||
| MYH9 and APOL1 are both associated with sickle cell disease nephropathy | Q37451162 | ||
| Abatacept in B7-1-positive proteinuric kidney disease | Q37633142 | ||
| Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. | Q43617519 | ||
| Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide | Q43784012 | ||
| Lithium-induced nephrotic syndrome in a young pediatric patient | Q43961785 | ||
| The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. | Q44640345 | ||
| Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial | Q44660764 | ||
| Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance | Q37651364 | ||
| Pathogenesis and therapy of focal segmental glomerulosclerosis: an update | Q37812564 | ||
| Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. | Q37822895 | ||
| Raised serum creatinine at presentation does not adversely affect steroid response in primary focal segmental glomerulosclerosis in adults | Q37908883 | ||
| Focal and segmental glomerulosclerosis: multiple pathways are involved | Q37916842 | ||
| Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients | Q37928188 | ||
| Focal segmental glomerulosclerosis | Q37970393 | ||
| Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms | Q37984206 | ||
| Pathobiology of focal segmental glomerulosclerosis: new developments | Q37987334 | ||
| Obesity and kidney disease: potential mechanisms | Q38078543 | ||
| Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults | Q38085054 | ||
| Serum suPAR in patients with FSGS: trash or treasure? | Q38091638 | ||
| Different targets for treating focal segmental glomerular sclerosis | Q38108170 | ||
| Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist | Q38192853 | ||
| Treatment of FSGS in Children | Q38193933 | ||
| The sclerosing glomerulus in mice and man: novel insights | Q38202839 | ||
| A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. | Q38233673 | ||
| Morphologic variants of focal segmental glomerulosclerosis and their significance. | Q38244351 | ||
| The treatment of idiopathic focal segmental glomerulosclerosis in adults | Q38244355 | ||
| Sleep apnea and the kidney: is sleep apnea a risk factor for chronic kidney disease? | Q38257377 | ||
| Causes and pathogenesis of focal segmental glomerulosclerosis | Q38275115 | ||
| Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy | Q38397636 | ||
| Collapsing Focal Segmental Glomerulosclerosis in a Patient with Acute Malaria | Q38559522 | ||
| Mechanical challenges to the glomerular filtration barrier: adaptations and pathway to sclerosis | Q38786437 | ||
| Defining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology | Q38821066 | ||
| Computational simulation of renal biopsy accuracy in focal segmental glomerulosclerosis | Q39120807 | ||
| Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1. | Q39189360 | ||
| Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome | Q39398182 | ||
| Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population | Q39801045 | ||
| A study of interobserver reproducibility of morphologic lesions of focal segmental glomerulosclerosis. | Q40082066 | ||
| Direct effects of dexamethasone on human podocytes | Q40256235 | ||
| The evolution of morphological variants of focal segmental glomerulosclerosis: a repeat biopsy-based observation. | Q40752049 | ||
| Primary focal segmental glomerulosclerosis: pathology, histological variants, and pathogenesis | Q40784815 | ||
| Nephron mass as a risk factor for progression of renal disease | Q41667489 | ||
| Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family. | Q42254379 | ||
| Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. | Q42616843 | ||
| A role for genetic susceptibility in sporadic focal segmental glomerulosclerosis | Q42930267 | ||
| Viruses and collapsing glomerulopathy: a brief critical review | Q43101728 | ||
| P433 | issue | 3 | |
| P921 | main subject | focal segmental glomerulosclerosis | Q1435223 |
| P304 | page(s) | 502-517 | |
| P577 | publication date | 2017-02-27 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | Focal Segmental Glomerulosclerosis. | |
| P478 | volume | 12 |
| Q92956379 | A bigenic mouse model of FSGS reveals perturbed pathways in podocytes, mesangial cells and endothelial cells |
| Q92932670 | A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis |
| Q64108710 | A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosis |
| Q58778381 | Activation of mineralocorticoid receptor by ecdysone, an adaptogenic and anabolic ecdysteroid, promotes glomerular injury and proteinuria involving overactive GSK3β pathway signaling |
| Q96430856 | Adverse events following immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV®) in Taiwan, 2017-18 |
| Q92884399 | Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice |
| Q52561530 | Application of next-generation sequencing technology to diagnosis and treatment of focal segmental glomerulosclerosis. |
| Q98292928 | Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis |
| Q97681325 | Autophagy in kidney homeostasis and disease |
| Q91796131 | Autosomal Dominant Tubulointerstitial Kidney Disease-Uromodulin Misclassified as Focal Segmental Glomerulosclerosis or Hereditary Glomerular Disease |
| Q92545417 | Auxiliary genetic analysis in a Chinese adolescent NPH family by single nucleotide polymorphism screening |
| Q92109722 | Chondroitin sulfate degradation and eicosanoid metabolism pathways are impaired in focal segmental glomerulosclerosis: Experimental confirmation of an in silico prediction |
| Q90288511 | Development of a Cell-Based Assay for the Detection of Neutralizing Antibodies to PF-06730512 Using Homogenous Time-Resolved Fluorescence |
| Q92074420 | Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study |
| Q92405079 | Disease Recurrence-The Sword of Damocles in Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis |
| Q96303369 | Distinct Functional Requirements for Podocalyxin in Immature and Mature Podocytes Reveal Mechanisms of Human Kidney Disease |
| Q47659086 | Distribution of glomerular diseases in Taiwan: preliminary report of National Renal Biopsy Registry-publication on behalf of Taiwan Society of Nephrology |
| Q64901830 | Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS. |
| Q91174305 | Genetic Ablation of Calcium-independent Phospholipase A2γ Exacerbates Glomerular Injury in Adriamycin Nephrosis in Mice |
| Q52588359 | Genetic Testing in Clinical Settings. |
| Q91708296 | Genome-Wide Study Updates in the International Genetics and Translational Research in Transplantation Network (iGeneTRAiN) |
| Q89812764 | Glomerular Disease Pathology in the Era of Proteomics: From Pattern to Pathogenesis |
| Q90458584 | Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis |
| Q91981900 | Inflammation Induces Lipid Deposition in Kidneys by Downregulating Renal PCSK9 in Mice with Adriamycin-Induced Nephropathy |
| Q95660603 | Inhibition of mTOR delayed but could not prevent experimental collapsing focal segmental glomerulosclerosis |
| Q51840896 | Investigational drugs in development for focal segmental glomerulosclerosis. |
| Q92853737 | Lysophosphatidic Acid Signaling in Diabetic Nephropathy |
| Q57189799 | Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: Role of NADPH oxidases and Src family tyrosine kinases |
| Q101133404 | Mild electrical stimulation with heat shock attenuates renal pathology in adriamycin-induced nephrotic syndrome mouse model |
| Q51733588 | New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. |
| Q92016493 | Podocyte RNA sequencing reveals Wnt- and ECM-associated genes as central in FSGS |
| Q92631461 | Post-Translational Modification and Natural Mutation of TRPC Channels |
| Q92354723 | Prevalence rates of histopathologic subtypes associated with steroid resistance in childhood nephrotic syndrome in Sub-Saharan Africa: a systematic review |
| Q64929779 | Prospects of genetic testing for steroid-resistant nephrotic syndrome in Nigerian children: a narrative review of challenges and opportunities. |
| Q57652246 | Proteinuric Kidney Diseases: A Podocyte's Slit Diaphragm and Cytoskeleton Approach |
| Q89663499 | Proteome Analysis of Isolated Podocytes Reveals Stress Responses in Glomerular Sclerosis |
| Q49772713 | Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome |
| Q90750202 | Rare inherited kidney diseases: an evolving field in Nephrology |
| Q54151193 | Resveratrol Attenuates Adriamycin-Induced Focal Segmental Glomerulosclerosis through C3aR/C5aR- Sphingosine Kinase 1 Pathway. |
| Q90597684 | Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis |
| Q91796100 | Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis |
| Q90721868 | The Role of MicroRNAs in Selected Forms of Glomerulonephritis |
| Q55394744 | The Spectrum of Focal Segmental Glomerulosclerosis from Eastern India: Is It Different? |
| Q90707886 | The Symptoms and Impact of Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Conceptual Model of the Patient Experience |
| Q92445005 | The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes |
| Q53684500 | The renal manifestations of type 4 familial partial lipodystrophy: a case report and review of literature. |
| Q91520925 | Therapeutic plasma exchange: Review of current indications |
| Q99549625 | Toll-Like Receptor as a Potential Biomarker in Renal Diseases |
| Q90589602 | Urinary ERdj3 and mesencephalic astrocyte-derived neutrophic factor identify endoplasmic reticulum stress in glomerular disease |
| Q92786961 | c-Src is in the effector pathway linking uPAR and podocyte injury |
Search more.